Skip to main content
OpenTrials
Completed

NCT Number: NCT04665050

Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)

The purpose of this study is to compare the safety, tolerability, and immunogenicity of a polyvalent pneumococcal conjugate vaccine (V116) with that of PNEUMOVAX™23 in healthy Japanese adults.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pneumococcal Infection Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Pneumococcal Infections Streptococcal Infections

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Souseikai PS Clinic ( Site 0201), Fukuoka, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • is a healthy Japanese male or female ≥20 years of age at time of randomization
  • male participants must agree to be abstinent or use contraception during the intervention period and for ≥30 days after the last dose of study intervention
  • female participants must not be pregnant or breastfeeding, and is either:
  • not a woman of childbearing potential (WOCBP) or
  • a WOCBP who agrees to remain abstinent or use contraception during the intervention period and for ≥30 days after the last dose of study intervention

Exclusion criteria

  • has a history of invasive pneumococcal disease (IPD) within 3 years of Day 1
  • has a known hypersensitivity to any vaccine components
  • has impaired immunological function
  • has a coagulation disorder
  • had a recent febrile illness (axillary temperature ≥37.5°C or equivalent) within 72 hours before Day 1
  • has a known malignancy that is progressing/requiring treatment
  • has received, or is expected to receive, a pneumococcal vaccine outside the study protocol
  • has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed the regimen for ≥30 days prior to Day 1
  • is receiving immunosuppressive therapy
  • has received any non-live vaccine from 14 days prior to Day 1 other than inactivated influenza vaccine
  • has received any live vaccine from 30 days prior to Day 1
  • has received a blood transfusion or blood products
  • has participated in another clinical trial within 2 months of this study
  • has clinically relevant drug or alcohol abuse
  • has any condition that, in the opinion of the investigator, precludes participation in this study

Treatment and study plan

V116

Biological

Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Other names: Polyvalent pneumococcal conjugate vaccine (pPCV), Pneumococcal 21-valent Conjugate Vaccine

PNEUMOVAX™23

Biological

Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

Other names: PPSV23

Primary outcomes

  1. Percentage of Participants With a Solicited Injection-site Adverse Event (AE)

    Time frame: Up to 5 days postvaccination

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included tenderness/pain, redness/erythema, and swelling. The percentage of participants with one or more solicited injection-site AE was reported for each arm.

  2. Percentage of Participants With a Solicited Systemic AE

    Time frame: Up to 5 days postvaccination

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle pain/myalgia, joint pain/arthralgia, and tiredness/fatigue. The percentage of participants with one or more solicited systemic AE was reported for each arm.

  3. Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)

    Time frame: Up to 62 days postvaccination

    An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs that were reported by the investigator to be at least possibly related to the study vaccination were reported.

Secondary outcomes

  1. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and PNEUMOVAX™23

    Time frame: Day 30 postvaccination

    The serotype-specific OPA GMTs for serotypes common to V116 and PNEUMOVAX™23 were determined using the multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group measures of dispersion (MOD) were not calculated.

  2. Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the Common Serotypes in V116 and PNEUMOVAX™23

    Time frame: Day 30 postvaccination

    The GMCs for serotype-specific pneumococcal IgG antibodies were measured using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.

  3. Serotype-specific OPA GMTs for the Unique Serotypes in V116

    Time frame: Day 30 postvaccination

    The serotype-specific OPA GMTs for serotypes unique to V116 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.

  4. Serotype-specific IgG GMCs for the Unique Serotypes in V116

    Time frame: Day 30 postvaccination

    The GMCs for serotype-specific pneumococcal IgG antibodies unique to V116 were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.

  5. Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA

    Time frame: Baseline (Day 1) and Day 30 postvaccination

    GMTs for the serotypes in V116 and PNEUMOVAX™23 were determined using the MOPA at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal serotype was calculated.

  6. GMFR From Baseline in Serotype-specific IgG GMCs

    Time frame: Baseline (Day 1) and Day 30 postvaccination

    GMCs for the serotypes in V116 and PNEUMOVAX™23 were measured by PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMC/Day 1 GMC) from baseline (Day 1) to Day 30 of each pneumococcal serotype was calculated.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Phase 1, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults.

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Dec 11, 2020
Registry last updated
Oct 4, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.